检查点抑制时代的玻璃体内皮肤转移性黑色素瘤:暴露与伪装
这项多中心回顾性队列研究纳入11例患者14眼玻璃体转移性皮肤黑色素瘤,中位年龄66岁,10例曾接受免疫检查点抑制。眼部治疗包括外照射放疗、玻璃体内美法仑等,最终视力从20/20至无光感,约四分之一患者眼部病变先于中枢神经系统转移。
要点
- 玻璃体碎屑在转移性皮肤黑色素瘤背景下需鉴别玻璃体内转移,检查点抑制时代似更明显。
- 外照射放疗、玻璃体内美法仑和全身检查点抑制可用于眼部病变治疗。
- 可发生新生血管性青光眼和视网膜脱离,多数眼视力预后差。
核心结论
- 转移性皮肤黑色素瘤背景下玻璃体碎屑的鉴别诊断包括玻璃体内转移,这在检查点抑制治疗时代似乎尤为明显。
- 外照射放疗、玻璃体内美法仑和全身检查点抑制可用于眼部疾病治疗,新生血管性青光眼和视网膜脱离可能发生,多数眼视力预后差。
- 约四分之一患者眼部疾病先于中枢神经系统转移出现,有视觉症状或玻璃体碎屑的转移性皮肤黑色素瘤患者将从眼肿瘤专科评估中获益。
研究设计与样本
- 多中心、回顾性队列研究,纳入11例患者14眼玻璃体转移性皮肤黑色素瘤。
- 回顾性审查临床记录包括眼底照相和超声结果,记录每只患者眼的相关数据。
主要发现
- 眼部疾病就诊中位年龄66岁(范围23-88岁),眼部疾病诊断后中位随访23个月。
- 11例患者中10例在治疗过程中曾接受免疫检查点抑制,从开始免疫治疗至眼部症状的中位时间为17个月(范围4.5-38个月)。
- 半数眼显示无色素性玻璃体碎屑,5眼眼压升高,4眼视网膜脱离,6例患者显示中枢神经系统转移。
- 眼部治疗包括6眼外照射放疗(30-40 Gy)、4眼玻璃体内美法仑(10-20 μg)、1眼眼球摘除、2眼全身治疗期间局部观察,3眼因新生血管形成接受玻璃体内贝伐珠单抗。
- 最终Snellen视力范围从20/20至无光感。
临床怎么用
- 作者认为,转移性皮肤黑色素瘤背景下出现视觉症状或玻璃体碎屑的患者将从眼肿瘤专科评估中获益。
- 作者指出,外照射放疗、玻璃体内美法仑和全身检查点抑制可用于眼部疾病治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Cutaneous melanoma metastatic to the vitreous is very rare. This study investigated the clinical findings, treatment, and outcome of patients with metastatic cutaneous melanoma to the vitreous. Most patients received checkpoint inhibition for the treatment of systemic disease, and the significance of this was explored. DESIGN: Multicenter, retrospective cohort study. PARTICIPANTS: Fourteen eyes of 11 patients with metastatic cutaneous melanoma to the vitreous. METHODS: Clinical records, including fundus photography and ultrasound results, were reviewed retrospectively, and relevant data were recorded for each patient eye. MAIN OUTCOME MEASURES: Clinical features at presentation, ophthalmic and systemic treatments, and outcomes. RESULTS: The median age at presentation of ophthalmic disease was 66 years (range, 23-88 years), and the median follow-up from diagnosis of ophthalmic disease was 23 months. Ten of 11 patients were treated with immune checkpoint inhibition at some point in the treatment course. The median time from starting immunotherapy to ocular symptoms was 17 months (range, 4.5-38 months). Half of eyes demonstrated amelanotic vitreous debris. Five eyes demonstrated elevated intraocular pressure, and 4 eyes demonstrated a retinal detachment. Six patients showed metastatic disease in the central nervous system. Ophthalmic treatment included external beam radiation (30-40 Gy) in 6 eyes, intravitreous melphalan (10-20 μg) in 4 eyes, enucleation of 1 eye, and local observation while receiving systemic treatment in 2 eyes. Three eyes received intravitreous bevacizumab for neovascularization. The final Snellen visual acuity ranged from 20/20 to no light perception. CONCLUSIONS: The differential diagnosis of vitreous debris in the context of metastatic cutaneous melanoma includes intravitreal metastasis, and this seems to be particularly apparent during this era of treatment with checkpoint inhibition. External beam radiation, intravitreous melphalan, and systemic checkpoint inhibition can be used in the treatment of ophthalmic disease. Neovascular glaucoma and retinal detachments may occur, and most eyes show poor visual potential. Approximately one quarter of patients demonstrated ocular disease that preceded central nervous system metastasis. Patients with visual symptoms or vitreous debris in the context of metastatic cutaneous melanoma would benefit from evaluation by an ophthalmic oncologist.
引用
- Francis JH, Berry D, Abramson DH, et al. Intravitreous Cutaneous Metastatic Melanoma in the Era of Checkpoint Inhibition: Unmasking and Masquerading. Ophthalmology. 2019. PMID: 31708274. doi:10.1016/j.ophtha.2019.09.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。